Catalyst Event
Illumina Inc (ILMN) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/28/2026, 12:00:00 AM
On 2026-04-28, Illumina's Board of Directors authorized an additional $1.5 billion for share repurchases; low impact (1-2%) estimated as buybacks typically provide modest price support expected.
Korean Translation
2026-04-28, 일루미나 이사회는 15억 달러 규모의 추가 자사주 매입을 승인함; 자사주 매입에 따른 1~2% 수준의 완만한 주가 영향이 예상됨.
Related Recent Events
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date for the final dividend of RMB 1.43 per share for the fiscal year 2025 on 2026-06-16, scheduled.
6/16/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
Annual General Meeting to be held on 2026-05-21 to review reports and approve plans; routine meetings typically have a 1-5% price impact, scheduled
5/21/2026, 12:00:00 AM
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
An earnings briefing for the 2025 fiscal year and Q1 2026 results is scheduled for May 14, 2026. This routine communication event is estimated to have a price impact of at least 1% scheduled.
5/14/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
Caris Life Sciences to report first quarter 2026 financial results on May 7, 2026, scheduled.
5/7/2026, 12:00:00 AM
Guardant Health Inc (GH) · Earnings Release
Guardant Health is scheduled to release its Q1 2026 financial results after market close on May 7, 2026. Analysts forecast EPS of ($0.47) and revenue of $279.17 million. High importance estimated due to potential for significant volatility following earnings results, scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is scheduled to release its first quarter 2026 financial results after the market closes on May 7, 2026, with analysts forecasting revenue of approximately $617.5 million and an EPS of -$0.55; high importance is expected due to typical earnings volatility, scheduled.
5/7/2026, 12:00:00 AM